Capricor Therapeutics has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CAPR:
- Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
- Biotech Alert: Searches spiking for these stocks today
- Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- CAPR Upcoming Earnings Report: What to Expect?
- Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7